Xencor, Inc. (NASDAQ:XNCR) Receives $22.25 Average Target Price from Analysts

Key Points

• Xencor, Inc. has received a consensus recommendation of "Moderate Buy" from analysts, with an average twelve-month target price of $22.25.
• Recent earnings showed that Xencor reported ($0.41) earnings per share, beating expectations, and a revenue increase of 82.4% year-over-year.
• Several large investors have significantly increased their holdings in Xencor, including CWM LLC, which grew its stake by 195.5% during the first quarter.

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has received an average rating of "Moderate Buy" from the nine ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $22.25.

Several research firms recently weighed in on XNCR. Bank of America cut Xencor from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $23.00 to $12.00 in a research report on Wednesday, September 3rd. Wedbush reaffirmed an "outperform" rating and issued a $26.00 price target on shares of Xencor in a report on Tuesday, September 2nd. Royal Bank Of Canada cut their price target on Xencor from $32.00 to $15.00 and set an "outperform" rating for the company in a report on Thursday, August 21st. Wells Fargo & Company dropped their target price on Xencor from $33.00 to $27.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Finally, Barclays initiated coverage on Xencor in a report on Wednesday. They issued an "underweight" rating and a $6.00 target price for the company.

Hedge Funds Weigh In On Xencor

Hedge funds have recently modified their holdings of the stock. Braidwell LP grew its position in Xencor by 169.0% during the 1st quarter. Braidwell LP now owns 1,655,690 shares of the biopharmaceutical company's stock worth $17,617,000 after acquiring an additional 1,040,159 shares during the last quarter. Primecap Management Co. CA increased its holdings in Xencor by 8.6% during the 1st quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company's stock valued at $103,857,000 after purchasing an additional 776,580 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in Xencor by 452.4% during the 4th quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company's stock valued at $19,236,000 after purchasing an additional 685,557 shares in the last quarter. Nantahala Capital Management LLC acquired a new stake in Xencor during the 1st quarter valued at $4,860,000. Finally, Bank of America Corp DE increased its holdings in Xencor by 94.5% during the 2nd quarter. Bank of America Corp DE now owns 938,993 shares of the biopharmaceutical company's stock valued at $7,380,000 after purchasing an additional 456,302 shares in the last quarter.

Xencor Stock Performance

Shares of Xencor stock traded up $0.26 during trading on Tuesday, hitting $10.29. 4,502,615 shares of the stock traded hands, compared to its average volume of 883,283. The stock has a market cap of $733.88 million, a P/E ratio of -4.29 and a beta of 0.82. Xencor has a twelve month low of $6.92 and a twelve month high of $27.24. The company has a fifty day moving average price of $8.38 and a two-hundred day moving average price of $9.21.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.37. The business had revenue of $43.61 million during the quarter, compared to analyst estimates of $22.59 million. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The firm's revenue was up 82.4% on a year-over-year basis. During the same period in the previous year, the company earned ($1.07) EPS. On average, equities research analysts expect that Xencor will post -3.68 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.